Edge Therapeutics (EDGE) Lifted to “Buy” at BidaskClub

BidaskClub upgraded shares of Edge Therapeutics (NASDAQ:EDGE) from a hold rating to a buy rating in a research note issued to investors on Monday morning.

A number of other analysts have also recently issued reports on EDGE. Zacks Investment Research upgraded shares of Edge Therapeutics from a sell rating to a buy rating and set a $12.00 target price for the company in a research note on Monday, November 6th. Credit Suisse Group reiterated an outperform rating and issued a $17.00 target price on shares of Edge Therapeutics in a research note on Thursday, January 18th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $20.00.

Shares of Edge Therapeutics (NASDAQ:EDGE) opened at $13.50 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34. Edge Therapeutics has a one year low of $7.30 and a one year high of $13.76.

In other news, insider Brian A. Leuthner sold 5,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $10.11, for a total value of $50,550.00. Following the completion of the sale, the insider now directly owns 87,736 shares in the company, valued at $887,010.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian A. Leuthner sold 2,500 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $13.14, for a total transaction of $32,850.00. Following the completion of the sale, the chief executive officer now owns 82,736 shares of the company’s stock, valued at $1,087,151.04. The disclosure for this sale can be found here. Insiders sold 20,861 shares of company stock valued at $215,760 over the last quarter. Corporate insiders own 36.19% of the company’s stock.

Several institutional investors have recently modified their holdings of EDGE. Schwab Charles Investment Management Inc. lifted its stake in shares of Edge Therapeutics by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock worth $773,000 after buying an additional 532 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Edge Therapeutics by 19.1% in the second quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock worth $205,000 after buying an additional 3,195 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of Edge Therapeutics by 21.1% in the second quarter. Teachers Advisors LLC now owns 34,329 shares of the biotechnology company’s stock worth $352,000 after buying an additional 5,976 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Edge Therapeutics by 12.8% in the second quarter. TIAA CREF Investment Management LLC now owns 50,210 shares of the biotechnology company’s stock worth $515,000 after buying an additional 5,705 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new stake in shares of Edge Therapeutics in the second quarter worth $106,000. Institutional investors and hedge funds own 50.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/02/08/edge-therapeutics-edge-lifted-to-buy-at-bidaskclub.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply